R/R NHL: gemcitabine-based salvage therapy yields 37% ORR in Israeli study

  • Zlotnick M & al.
  • Acta Haematol
  • 10 Jan 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A retrospective case-series finds an overall response rate (ORR) of 37% in patients given gemcitabine-based salvage chemotherapy for relapsed and refractory non-Hodgkin lymphoma (R/R NHL).

Why this matters

  • Most studies report 50% or better ORR in this patient population.
  • Better therapies are urgently needed.

Study design

  • Retrospective, consecutive case-series of 41 patients with R/R aggressive NHL given gemcitabine-based regimens from 2007 to 2015 at an Israeli hospital.
  • Funding: None disclosed.

Key results

  • Median follow-up was 218 days; median age was 66.4 years.
  • 73% of patients had B-cell and 27% had T-cell NHL; all had received a median of 2 prior regimens, 1 of which was anthracycline-based.
  • The ORR was 36.6%, with 24.4% having complete response and 12.2% having partial response; the remainder had progressive or stable disease.
  • Median PFS was 47 days (range, 12-1318 days); median OS was 1.9 years (range, 0.03-4 years).
  • Treatment with a full-dose regimen was associated with superior OS (χ2, 7.33; P=.007).
  • 51.2% had grade 3-4 hematological toxicity.
  • 48.8% of patients died during follow-up.

Limitations

  • Single-center study.
  • Observational design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit